University of California San Diego

Running trials

• Not yet recruiting

  Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia

  NCT07659938· BioSignal Solutions LLC· Source

• Recruiting

  Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia

  NCT07592169· Phase 2· University of California, San Diego· Source

• Not yet recruiting

  Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

  NCT07870746· Phase 2· Telix Pharmaceuticals (Innovations) Pty Limited· Source

• Not yet recruiting

  Optimizing CBSST With Executive Function Training for Schizophrenia (R33)

  NCT07658391· University of California, San Diego· Source

• Not yet recruiting

  Signatera Assessment in Early-Stage Endometrial Cancer

  NCT07339384· Natera, Inc.· Source

• Recruiting

  Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis

  NCT07756567· University of California, San Diego· Source

• Enrolling by invitation

  Effects of Mental Tasks on Breathing Patterns in Adults Using Chronic Opioids vs Non-opioid Users.

  NCT07829055· University of California, San Diego· Source

• Recruiting

  Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

  NCT07804186· Phase 3· IDEAYA Biosciences· Source

• Recruiting

  ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

  NCT07021989· Phase 2· Michael Spinner, MD· Source

• Recruiting

  Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

  NCT07364071· Phase 2· University of California, San Diego· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Not yet recruiting

  An mHealth Intervention to Improve HIV Prevention Service Engagement Among People Who Use Drugs

  NCT06068283· University of California, San Diego· Source

• Recruiting

  Prospective Natural History Study of POLG Disease

  NCT07775872· The POLG Foundation· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Not yet recruiting

  Folate Study in Men With Advanced Prostate Cancer

  NCT06536374· Phase 2· University of California, San Diego· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT06790602· Phase 2· University of California, San Diego· Source

• Recruiting

  U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures

  NCT07325578· Precision IO Group· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

  NCT07137338· Phase 1· Rocket Pharmaceuticals Inc.· Source

• Recruiting

  Behavioral Interventions Combining AI/ML and Personalized Medicine to Reduce Cardiovascular Risk - Randomized Controlled Trial

  NCT07725250· National Bureau of Economic Research, Inc.· Source

• Recruiting

  Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

  NCT07227233· Phase 2· University of California, San Diego· Source

• Recruiting

  Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

  NCT07312734· Chris Goss· Source

• Recruiting

  Endotype DIrected Treatment for OSA in Down Syndrome

  NCT07280468· Phase 4· University of Arizona· Source

• Recruiting

  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

  NCT06863311· Phase 2· Karie Runcie· Source

• Recruiting

  Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

  NCT07477639· Phase 1/2· Tr1X, Inc.· Source

• Recruiting

  Nutritional Intervention for College Students With Depression

  NCT07490782· University of California, San Diego· Source

• Recruiting

  Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  NCT07287917· Phase 1/2· Aminex Therapeutics, Inc.· Source

• Recruiting

  Blood Pressure Care for Advancing Real-World Evidence (BPCARE)

  NCT07398391· University of California, San Diego· Source

• Recruiting

  Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

  NCT07335601· Phase 2· Madrigal Pharmaceuticals, Inc.· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Automated Insulin for Management of Intrapartum Glycemia

  NCT06883344· University of California, San Francisco· Source

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

  NCT07142291· Phase 2· PhenoNet, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Vivio At-Home Study

  NCT07730268· Ventric Health, LLC· Source

• Recruiting

  Closed Loop and Education for Hypoglycemia Awareness Restoration

  NCT06325202· Milton S. Hershey Medical Center· Source

• Recruiting

  Clinical Course Of Disease In Participants With FA-CM

  NCT06865482· Lexeo Therapeutics· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

  NCT06837181· Jaeb Center for Health Research· Source

• Enrolling by invitation

  Head to Head Trial of Mailed Cologuard to Mailed FIT

  NCT06931860· University of California, San Diego· Source

• Recruiting

  A Study of GNTI-122 in Adults Recently Diagnosed With T1D

  NCT06919354· Phase 1· GentiBio, Inc· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy

  NCT07098169· University of California, San Diego· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Implementing Food Referrals for Equity and Sustained Health

  NCT06661538· Phase 2· University of California, San Diego· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy

  NCT07121543· University of California, San Diego· Source

• Recruiting

  Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer

  NCT06824974· University of California, San Diego· Source

• Recruiting

  Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)

  NCT06865937· University of California, San Diego· Source

Showing 50 of 250.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer11 recruiting
• Schizophrenia9 recruiting
• Heart failure6 recruiting
• Metastatic breast cancer6 recruiting
• Parkinson disease6 recruiting
• ALS (motor neurone disease)5 recruiting
• Colorectal cancer5 recruiting
• Epilepsy5 recruiting
• Lung cancer5 recruiting
• Pancreatic cancer5 recruiting
• Cystic fibrosis4 recruiting
• Fatty liver disease (MASLD/MASH)4 recruiting
• Glioblastoma4 recruiting
• HIV4 recruiting
• Kidney cancer4 recruiting
• Melanoma4 recruiting
• Acute myeloid leukaemia3 recruiting
• Alzheimer disease3 recruiting
• Childhood cancers3 recruiting
• Crohn's disease3 recruiting
• Depression3 recruiting
• Multiple myeloma3 recruiting
• Obesity3 recruiting
• Obstructive sleep apnoea3 recruiting
• Psoriasis3 recruiting
• Stroke3 recruiting
• Type 1 diabetes3 recruiting
• Type 2 diabetes3 recruiting
• Aortic aneurysm2 recruiting
• Cervical cancer2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Endometrial cancer2 recruiting
• Frontotemporal dementia2 recruiting
• Head and neck cancer2 recruiting
• High blood pressure2 recruiting
• Hodgkin lymphoma2 recruiting
• Huntington's disease2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lupus (SLE)2 recruiting
• Ovarian cancer2 recruiting
• Psoriatic arthritis2 recruiting
• Triple-negative breast cancer2 recruiting
• Ulcerative colitis2 recruiting
• Vascular dementia2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alopecia areata1 recruiting
• Aortic stenosis1 recruiting
• Aplastic anaemia1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Autism1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Dilated cardiomyopathy1 recruiting
• Down syndrome1 recruiting
• Friedreich ataxia1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hearing loss1 recruiting
• Hepatitis C1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Multiple sclerosis1 recruiting
• Myocarditis1 recruiting
• Osteoporosis1 recruiting
• Retinitis pigmentosa1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting
• Spinal cord injury1 recruiting

Closed trials

• Withdrawn

  Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

  NCT07803562· Phase 2· University of California, San Diego· Source

• Completed

  Accurate Point of Care Liver Disease Diagnostics (Phase 2)

  NCT07518784· University of California, San Diego· Source

• Completed

  A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

  NCT06791122· Boehringer Ingelheim· Source

• Completed

  Food Is Medicine for Patients With Heart Failure

  NCT06540118· University of California, San Diego· Source

• Completed

  Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation

  NCT06560411· Breas Medical, Inc.· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Hoffmann-La Roche· Source

• Completed

  Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

  NCT06947382· Immunovia, Inc.· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Alumis Inc· Source

• Completed

  Head to Head Pilot Trial of Mailed Cologuard to Mailed FIT

  NCT06173375· University of California, San Diego· Source

• Recruiting

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Withdrawn

  Intraperitoneal LSTA1 in CRS-HIPEC

  NCT06216561· Phase 1· University of California, San Diego· Source

• Completed

  Managing Opioid Related Sleep Apnea With Acetazolamide

  NCT06043830· Phase 2· University of California, San Diego· Source

• Completed

  iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders

  NCT05899348· University of California, San Diego· Source

• Completed

  Frequency and E-field Enhancement of ITBS for Depression (FREED)

  NCT06003309· University of California, San Diego· Source

• Terminated

  Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

  NCT05935748· Phase 2· NiKang Therapeutics, Inc.· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

  NCT05856448· Phase 2· Lakefront Biotherapeutics NV· Source

• Completed

  Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

  NCT05671835· Phase 2· Tvardi Therapeutics, Incorporated· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Recruiting

  A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

  NCT05440708· Phase 1/2· Tvardi Therapeutics, Incorporated· Source

• Completed

  Feasibility of a Whole-Food, Plant-Based Diet for Patients With Low-Risk Chronic Lymphocytic Leukemia (CLL)

  NCT06377501· University of California, San Diego· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· COMPASS Pathways· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Biomea Fusion Inc.· Source

• Completed

  A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

  NCT05578872· Phase 1/2· Anaveon AG· Source

• Completed

  Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

  NCT05436535· Phase 4· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism

  NCT05568927· University of California, San Diego· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Edgewise Therapeutics, Inc.· Source

• Completed

  A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

  NCT05453578· Phase 1/2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Cognitive Disparities in Parkinson's Disease

  NCT07262658· Duke University· Source

• Completed

  Improving Germline Testing in At-Risk Patients With Prostate Cancer

  NCT05470036· University of California, San Diego· Source

• Completed

  Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

  NCT05281614· Early phase 1· Benaroya Research Institute· Source

• Completed

  Treating Pediatric NAFLD with Nutrition

  NCT05499585· University of California, San Diego· Source

• Completed

  Vitamin E Dosing Study

  NCT04801849· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness

  NCT05660070· University of California, San Diego· Source

• Completed

  Study of ATH434 in Participants with Multiple System Atrophy

  NCT05109091· Phase 2· Alterity Therapeutics· Source

• Terminated

  Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

  NCT05156905· Phase 1· University of California, San Diego· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

  NCT05358717· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

  NCT05070247· Phase 1/2· Takeda· Source

• Completed

  IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

  NCT05077709· Phase 2· IO Biotech· Source

• Completed

  Onboarding Positives and PrEP Users to Engage Negatives (OPPEN): Peer-driven Education to Link YMSM of Color to PrEP

  NCT05356910· University of California, San Diego· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Marinus Pharmaceuticals· Source

• Terminated

  Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

  NCT05169437· Phase 2· Tempus AI· Source

• Terminated

  Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

  NCT04930445· Pfizer· Source

• Terminated

  PRV-3279-2a Trial in Systemic Lupus

  NCT05087628· Phase 2· Provention Bio, a Sanofi Company· Source

• Completed

  Human Sodium Balance Study

  NCT04110262· University of California, San Diego· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

  NCT05025787· Phase 2· Maurizio Fava, MD· Source

• Completed

  XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT05005728· Phase 2· Xencor, Inc.· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Terminated

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

  NCT04951609· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

  NCT05006352· Phase 1· Denali Therapeutics Inc.· Source

Showing 50 of 111.

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease403 works · 10 trials
• HIV349 works · 14 trials
• Obesity271 works · 10 trials
• Stroke215 works · 7 trials
• Prostate cancer173 works · 21 trials
• Lung cancer152 works · 27 trials
• Heart failure139 works · 15 trials
• Type 2 diabetes123 works · 5 trials
• Liver and biliary tract cancer117 works · 7 trials
• Fatty liver disease (MASLD/MASH)108 works · 16 trials
• Asthma108 works · 1 trial
• Colorectal cancer105 works · 13 trials
• Pancreatic cancer98 works · 12 trials
• Schizophrenia91 works · 17 trials
• Obstructive sleep apnoea88 works · 8 trials
• Parkinson disease86 works · 11 trials
• Atopic dermatitis (eczema)86 works · 2 trials
• Glaucoma85 works · 1 trial
• Kidney cancer84 works · 11 trials
• Chronic kidney disease78 works · 1 trial
• Melanoma73 works · 17 trials
• Epilepsy69 works · 7 trials
• Bipolar disorder55 works · 3 trials
• Psoriasis48 works · 8 trials
• Triple-negative breast cancer44 works · 2 trials
• Depression44 works · 11 trials
• Ovarian cancer43 works · 7 trials
• Coronary artery disease41 works · 10 trials
• Tuberculosis40 works · 0 trials
• Glioblastoma39 works · 5 trials